| Shi, Yang |
TQH3906-Ib-01, NCT06754891: Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease |
|
|
| Not yet recruiting | 1 | 116 | RoW | TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Inflammatory Bowel Diseases | 12/26 | 12/27 | | |
| Li, Shanshan |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
VGR-R01-301, NCT06699108: Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy |
|
|
| Not yet recruiting | 3 | 45 | RoW | VGR-R01 | Shanghai Vitalgen BioPharma Co., Ltd. | Bietti Crystalline Dystrophy, Inherited Retinal Diseases | 12/26 | 06/27 | | |
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 2 | 41 | RoW | BDB-001 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 08/23 | 08/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 1/2 | 50 | RoW | BDB-001 Injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 07/23 | 07/23 | | |
